Patent US5147867A successfully refreshed from Google Patents.
US5147867A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Phosphorus containing enzyme inhibitors
Assignee: Merck and Co Inc
•
Filing: 1992-01-21
•
Granted: 1992-09-15
•
Expires: 2012-01-21
Abstract
Abstract Dipeptide mimics which contain phosphorus and their pharmaceutical use and preparation are disclosed. The compounds have dehydropeptidase (DHP) enzyme inhibitor activity.
Inventors
- 👤 William H. Parsons
- 👤 William R. Schoen
- 👤 Arthur A. Patchett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 05:26
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/30; C07F9/306; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; C07F9/301; C07F9/302; C07F9/303; C07F9/547; C07F9/553; C07F9/576; C07F9/58
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
372 words
A method of treatment for bacterial infections which comprises administering to a host a therapeutically effective amount of a DHP-inhibiting compound of Formula I, in combination with a therapeutically effective amount of a carbapenem or penem antibiotic: ##STR53## wherein: R 1 is (a) C 2 -C 12 linear or branched unsubstituted alkyl; (b) C 1 -C 12 linear or branched substituted alkyl; (c) C 2 -C 12 linear or branched monoalkenyl; (d) C 2 -C 12 linear or branched alkynyl; (e) C 7 -C 20 aralkyl, wherein the alkyl chain is linear or branched C 1 -C 8 and the aryl moiety is C 6 -C 12 ; (f) C 4 -C 10 cycloalkylalkyl; (g) C 3 -C 7 cycloalkyl; wherein said above values for R 1 , excluding (a), can be substituted by one or more: C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyloxy, C 3 -C 6 cycloalkylthio, C 6 -C 12 aryloxy, C 1 -C 4 alkylthio, C 6 -C 12 arylthio, C 7 -C 10 aralkyloxy, C 7 -C 16 aralkylthio; R 2 is (a) H or C 1 -C 12 linear or branched alkyl; (b) C 2 -C 12 linear or branched monoalkenyl; (c) C 7 -C 20 aralkyl, wherein the alkyl chain is linear or branched C 1 -C 8 and the aryl moiety is C 6 -C 12 ; (d) C 4 -C 10 cycloalkylalkyl; (e) C 3 -C 7 cycloalkyl; (f) heterocyclic alkyl, wherein the alkyl chain is linear or branched C 1 -C 8 and the heterocyclyl ring is 5-6 membered, optionally fused with a benzene ring, fully aromatic, containing 1-2: O, N or S heteroatoms; wherein said above values for R 2 can be substituted by one or more: halo, hydroxy, carboxy, C 1 -C 4 alkoxycarbonyl, C 7 -C 16 arylalkoxycarbonyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkoxy, C 6 -C 12 aryloxy, C 3 -C 6 cycloalkyloxy, C 3 -C 6 cycloalkylthio, amino, mono- or di-C 1 -C 8 alkylamino, thio, C 1 -C 4 alkylthio, C 6 -C 12 arylthio, C 7 -C 16 aralkylthio, or the radical --S--(CH 2 ) n --CH(NH 2 )COOH, and including DHP-inhibiting stereoisomers and racemates thereof Structure I.
Claim 2
Independent Claim
372 words
A method of treatment for bacterial infections which comprises administering to a host a therapeutically effective amount of a DHP-inhibiting compound of Formula I, in combination with a therapeutically effective amount of a carbapenem or penem antibiotic: ##STR53## wherein: R 1 is (a) C 2 -C 12 linear or branched unsubstituted alkyl; (b) C 1 -C 12 linear or branched substituted alkyl; (c) C 2 -C 12 linear or branched monoalkenyl; (d) C 2 -C 12 linear or branched alkynyl; (e) C 7 -C 20 aralkyl, wherein the alkyl chain is linear or branched C 1 -C 8 and the aryl moiety is C 6 -C 12 ; (f) C 4 -C 10 cycloalkylalkyl; (g) C 3 -C 7 cycloalkyl; wherein said above values for R 1 , excluding (a), can be substituted by one or more: C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyloxy, C 3 -C 6 cycloalkylthio, C 6 -C 12 aryloxy, C 1 -C 4 alkylthio, C 6 -C 12 arylthio, C 7 -C 10 aralkyloxy, C 7 -C 16 aralkylthio; R 2 is (a) H or C 1 -C 12 linear or branched alkyl; (b) C 2 -C 12 linear or branched monoalkenyl; (c) C 7 -C 20 aralkyl, wherein the alkyl chain is linear or branched C 1 -C 8 and the aryl moiety is C 6 -C 12 ; (d) C 4 -C 10 cycloalkylalkyl; (e) C 3 -C 7 cycloalkyl; (f) heterocyclic alkyl, wherein the alkyl chain is linear or branched C 1 -C 8 and the heterocyclyl ring is 5-6 membered, optionally fused with a benzene ring, fully aromatic, containing 1-2: O, N or S heteroatoms; wherein said above values for R 2 can be substituted by one or more: halo, hydroxy, carboxy, C 1 -C 4 alkoxycarbonyl, C 7 -C 16 arylalkoxycarbonyl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkoxy, C 6 -C 12 aryloxy, C 3 -C 6 cycloalkyloxy, C 3 -C 6 cycloalkylthio, amino, mono- or di-C 1 -C 8 alkylamino, thio, C 1 -C 4 alkylthio, C 6 -C 12 arylthio, C 7 -C 16 aralkylthio, or the radical --S--(CH 2 ) n --CH(NH 2 )COOH, and including DHP-inhibiting stereoisomers and racemates thereof Structure I.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein R 1 is cyclohexylmethyl, isobutyl, ethyl, benzyl, or
Claim 4
Dependent Claim
129 words
The method of claim 1 wherein: R 2 is C 1 -C 10 linear or branched alkyl; C 7 -C 14 aralkyl; wherein both groups can be substituted with halo, amino, mono- or di-C 1 -C 4 linear or branched alkylamino, carboxyl, C 1 -C 4 alkoxycarbonyl, hydroxy, C 1 -C 4 alkoxy, C 5 -C 6 cycloalkyl, C 6 -C 10 aryloxy, thio, C 1 -C 4 linear or branched alkylthio, C 6 -C 10 arylthio, C 7 -C 14 aralkylthio, --S--(CH 2 ) n --CH(NH 2 )CO 2 H, and wherein the aryl groups can further be substituted by linear or branched C 1 -C 4 alkyl; R 3 and R 4 are hydrogen, C 1 -C 4 linear or branched alkyl, C 7 -C 14 aralkyl.
Claim 5
Dependent Claim
33 words
The method of claim 1 in which the stereochemical configurations of the carbon attached to R 1 is (R) or (SR), and the carbon attached to R 2 is (R), (RS), or (S).
Claim 6
Dependent Claim
27 words
The method of claim 4 in which the stereochemical configurations of the carbon attached to R 1 is (R) and to R 2 is (S) or (RS).
Claim 7
Dependent Claim
48 words
The method of claim 1 in which the specific compound of Formula I is: 1-amino-3-methylbutyl-[2-carboxy-1-hexyl]phosphinic acid; 1-aminopropyl-[2-carboxy-4-phenyl-1-butyl]-phosphinic; 1-aminopropyl-[2-carboxy-1-butyl]phosphinic acid; 1-aminopropyl-[2-carboxy-1-hexyl]phosphinic acid; 1-aminopropyl-2-phenylethyl-[2-carboxy-1-hexyl]-phosphinic acid; (1-amino-2-cyclohexylethyl)-2-carboxy-5-(4-pyridyl)-pentyl phosphinic acid; 1-amino-2-cyclohexylethyl-[2-carboxy-5-(4-methyl)-1-pentyl phosphinic acid; (1-amino-2-cyclohexylethyl)-2-carboxy-3-cyclohexyl-1-propyl phosphinic acid; (1-amino-1-hexyl)-2-carboxy-1-octyl phosphinic acid; (1-amino-1-hexyl)-2-carboxy-4-cyclopentyl-1-butyl phosphinic acid; (1-amino-2-cyclohexylethyl)-2-carboxy-1-octyl phosphinic acid; (1-amino-2-cyclohexylethyl)-2-carboxy-4-cyclopentyl-1-butyl phosphinic acid; (1-amino-1-hexyl)-2-carboxy-3-cyclohexyl-1- propyl phosphinic acid.
Claim 8
Dependent Claim
34 words
A pharmaceutical composition for treatment of bacterial infections which comprises a therapeutically effective amount of a DHP-inhibiting compound of claim 1, in combination with a therapeutically effective amount of a carbapenem or penem antibiotic.
References Cited (Backward Citations)
US4147780A
Cited
US4160452A
Cited
US4256108A
Cited
US4265874A
Cited
US4539208A
Cited
US4374131A
Cited
US4416833A
Cited
EP0091594A1
Cited
EP0161546A1
Cited
EP0209848A2
Cited
EP0210545A2
Cited
US4715994A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-15 | 1996-03-16 | 1996-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-15 | 2000-03-16 | 2000-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-15 | 2004-03-16 | 2004-09-15 | $7700.00 | Window Closed / Lapsed |